BIOMAT Database Logo BIOMAT Database Logo

Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. 1990

C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden.

The gene for multiple endocrine neoplasia type 1 (MEN1), an inherited predisposition to neuroendocrine neoplasm of the parathyroid glands, the pancreatic islet parenchyma, and the anterior pituitary gland, was recently mapped to chromosome 11q13 based on genetic linkage in families. We now show that the pathogenesis of MEN1-associated parathyroid lesions involves unmasking of a recessive mutation at the disease locus and that sporadic primary hyperparathyroidism shares the same mechanisms. By examination of allele losses in MEN1-associated lesions, we could define deletions of chromosome 11 and map the MEN1 locus to a small region within chromosome band 11q13, telomeric to the PYGM locus. In contrast, a low incidence of deletions involving the MEN1 gene was found in sporadic pituitary adenomas.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009377 Multiple Endocrine Neoplasia A group of autosomal dominant diseases characterized by the combined occurrence of tumors involving two or more ENDOCRINE GLANDS that secrete PEPTIDE HORMONES or AMINES. These neoplasias are often benign but can be malignant. They are classified by the endocrine glands involved and the degree of aggressiveness. The two major forms are MEN1 and MEN2 with gene mutations on CHROMOSOME 11 and CHROMOSOME 10, respectively. Adenomatosis, Familial Endocrine,Endocrine Neoplasia, Multiple,Multiple Endocrine Neoplasia Syndrome,Neoplasia, Multiple Endocrine,Neoplasms, Multiple Endocrine,Adenomatosis, Multiple Endocrine,Familial Endocrine Adenomatosis,Multiple Endocrine Adenomatosis,Multiple Endocrine Adenopathy,Multiple Endocrine Neoplasia Syndromes,Multiple Endocrine Neoplasms,Adenomatoses, Familial Endocrine,Adenomatoses, Multiple Endocrine,Adenopathies, Multiple Endocrine,Adenopathy, Multiple Endocrine,Endocrine Adenomatoses, Familial,Endocrine Adenomatoses, Multiple,Endocrine Adenomatosis, Familial,Endocrine Adenomatosis, Multiple,Endocrine Adenopathies, Multiple,Endocrine Adenopathy, Multiple,Endocrine Neoplasms, Multiple,Familial Endocrine Adenomatoses,Multiple Endocrine Adenomatoses,Multiple Endocrine Adenopathies
D010282 Parathyroid Neoplasms Tumors or cancer of the PARATHYROID GLANDS. Cancer of Parathyroid,Parathyroid Cancer,Cancer of the Parathyroid,Neoplasms, Parathyroid,Parathyroid Adenoma,Parathyroid Carcinoma,Adenoma, Parathyroid,Adenomas, Parathyroid,Cancer, Parathyroid,Cancers, Parathyroid,Carcinoma, Parathyroid,Carcinomas, Parathyroid,Neoplasm, Parathyroid,Parathyroid Adenomas,Parathyroid Cancers,Parathyroid Carcinomas,Parathyroid Neoplasm
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D005260 Female Females

Related Publications

C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13.
June 1998, Genes, chromosomes & cancer,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Fine mapping of the MLK-3 gene within 11q13 and its exclusion as the MEN1 susceptibility gene.
June 1997, Human genetics,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients.
November 1996, Cancer research,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer.
August 2002, Oncogene,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Mapping of the ARIX homeodomain gene to mouse chromosome 7 and human chromosome 11q13.
May 1996, Genomics,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in the MEN1 gene.
September 1999, Genes, chromosomes & cancer,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
A 14-Mb physical map of the region at chromosome 11q13 harboring the MEN1 locus and the tumor amplicon region.
May 1992, Genomics,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Localization of the human phosphatidylinositol-specific phospholipase c beta 3 gene (PLCB3) within chromosome band 11q13.
January 1995, Genomics,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
A region within murine chromosome 7F4, syntenic to the human 11q13 amplicon, is frequently amplified in 4NQO-induced oral cavity tumors.
September 1997, Oncogene,
C Byström, and C Larsson, and C Blomberg, and K Sandelin, and U Falkmer, and B Skogseid, and K Oberg, and S Werner, and M Nordenskjöld
Mapping of the gene for multiple endocrine neoplasia type I to chromosome 11q13.
November 1989, Pathologie-biologie,
Copied contents to your clipboard!